Atherosclerotic Cardiovascular Disease research hub

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

This study is looking at a new medicine called Obicetrapib for people with heart disease. It aims to see if this medicine can help reduce serious heart problems like heart attacks and strokes, especially for those whose cholesterol isn't well-controlled with their usual treatments.

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

The REVEAL trial looked at whether a drug called anacetrapib could help people with existing heart and circulatory problems. It aimed to see if this drug, when added to usual statin treatment, could lower their risk of serious heart events like heart attacks. The study has now finished.

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

PLatelet aggregation and Aspirin low response in Type One Diabetes and the association with vascular damage and diabetic Nephropathy

This study looks at how blood clots form in people with Type 1 diabetes, especially those with kidney problems, to understand if aspirin works differently for them. It hopes to find out more about how these blood clots affect heart health and kidney disease.

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease

This study is testing a new medicine, AZD4144, for people who have both long-term kidney problems and heart disease caused by hardened arteries. We're looking at its safety, how well people tolerate it, and what it does in the body. It's a very early stage of research.

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

This study is following people who've had an experimental gene therapy for certain heart conditions. It checks how the treatment affects them over a long time, up to 15 years, looking for any lasting benefits or side effects to make sure it's safe and works well.

A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

This study, ORION-4, will test if a new injection called inclisiran can safely lower the risk of heart attacks and strokes in people who have already had these conditions or related treatments. It's for people with heart and blood vessel problems.